The present application is an ongoing project that will identify the molecular mechanisms responsible for osteoclast (OCL) inhibition by OCL inhibitory peptide-1 (OIP-1/hSca 1). During the previous proposal period, we have identified the OCL Inhibitory Peptide-1 (OIP-1/hSca), a local factor produced in the bone microenvironment as a novel inhibitor of OCL formation and bone resorption that is produced by OCLs. OIP-1 is a glycosylphosphatidyl-inositol (GPI) linked membrane protein (17 kDa) related to the Ly-6 family of hematopoietic proteins. We have determined that the OIP-1 c-peptide region (32 amino acids) of OIP-1 is critical for OIP-1's inhibition of OCL formation. Synthetic OIP-1 c-peptide inhibits OCL formation through suppression of TRAF-2 and p-c-Jun kinase activity, but has no effect on TRAF-6 and NF-kappaB activation. We also found that cytokines such as IFN-gamma, and IL-1beta significantly enhance OIP-1 mRNA expression in OCL precursors, CFU-GM. It is our hypothesis that OIP-1 plays a critical role in the physiologic regulation of OCL development by cellular signaling through unique transmembrane protein interactions and that OIP-1 expression in OCL precursors is controlled by specific transcriptional regulatory mechanisms. To test this hypothesis, we will pursue the following Specific Aims:
Aim (1) Identify and clone the osteoclast transmembrane proteins which interacts with the OIP-1 c-peptide: (i) Clone and characterize the osteoclast membrane receptor for OIP-1; (ii) Identify OIP-1 interacting proteins using yeast two-hybrid system; (iii) Determine the effects of over-expression or blocking the expression of OIP-1 interacting proteins on OIP-1 capacity to inhibit OCL formation (iv) Determine the participation of OIP-1 interacting proteins in OIP-1 signaling to inhibit OCL formation;
Aim (2) Determine if over-expression of OIP-1 in cells of OCL lineage inhibit osteoclast formation: (a) Develop TRAP-OIP-1 transgenic mice targeting OIP-1 expression in cells of OCL lineage to assess OCL development in vivo; (b) Determine if overexpression of OIP-1 in OCL precursor cells affects OCL differentiation and the status of RANKL signaling molecules during OCL differentiation in vitro;
Aim (3) Isolate and characterize the OIP-1 gene promoter sequence for cytokine regulatory regions and potential transcription factors that module OIP-1 gene expression in osteoclasts. These studies should provide important insights into the regulatory mechanisms responsible for OIP-1 inhibition of OCL formation in the bone microenvironment and allow development of novel rational approaches and therapeutic agents to control enhanced osteoclast activity in Paget's disease and other bone diseases such as osteoporosis and multiple myeloma.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
2R01DE012603-06A2
Application #
6819346
Study Section
Skeletal Biology Development and Disease Study Section (SBDD)
Program Officer
Shum, Lillian
Project Start
1999-04-10
Project End
2009-06-30
Budget Start
2004-09-24
Budget End
2005-06-30
Support Year
6
Fiscal Year
2004
Total Cost
$204,554
Indirect Cost
Name
Medical University of South Carolina
Department
Pediatrics
Type
Schools of Medicine
DUNS #
183710748
City
Charleston
State
SC
Country
United States
Zip Code
29425
Shanmugarajan, Srinivasan; Beeson, Craig C; Reddy, Sakamuri V (2010) Osteoclast inhibitory peptide-1 binding to the Fc gammaRIIB inhibits osteoclast differentiation. Endocrinology 151:4389-99
Hikata, Tomohiro; Takaishi, Hironari; Takito, Jiro et al. (2009) PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts. Blood 113:2202-12
Shanmugarajan, Srinivasan; Kawanabe, Noriaki; Koide, Masanori et al. (2009) IL-12 stimulates the osteoclast inhibitory peptide-1 (OIP-1/hSca) gene expression in CD4+ T cells. J Cell Biochem 107:104-11
Goldstein, Oliver G; Hajiaghamohseni, Laela M; Amria, Shereen et al. (2008) Gamma-IFN-inducible-lysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma. Cancer Immunol Immunother 57:1461-70
Shanmugarajan, Srinivasan; Youssef, Rimon F; Pati, Parmita et al. (2008) Osteoclast inhibitory peptide-1 (OIP-1) inhibits measles virus nucleocapsid protein stimulated osteoclast formation/activity. J Cell Biochem 104:1500-8
Shanmugarajan, S; Irie, K; Musselwhite, C et al. (2007) Transgenic mice with OIP-1/hSca overexpression targeted to the osteoclast lineage develop an osteopetrosis bone phenotype. J Pathol 213:420-8
Shanmugarajan, Srinivasan; Swoboda, Kathryn J; Iannaccone, Susan T et al. (2007) Congenital bone fractures in spinal muscular atrophy: functional role for SMN protein in bone remodeling. J Child Neurol 22:967-73
Srinivasan, Shanmugarajan; Ito, Masahiro; Kajiya, Hiroshi et al. (2006) Functional characterization of human osteoclast inhibitory peptide-1 (OIP-1/hSca) gene promoter. Gene 371:16-24
Schaub, R; Dupont, B; Roodman, G D et al. (2000) Assignment of OSTF1 to human chromosome bands 12q24.1-->q24.2 by in situ hybridization. Cytogenet Cell Genet 88:87-8